This report is based on the proceedings of a workshop that was sponsored by the Forum on Emerging Infections. It is prepared in the form of a workshop summary by and in the name of the editor with the assistance of staff and consultants, as an individually authored document. Sections of the workshop summary not specifically attributed to an individual reflect the views of the editor and not those of the Forum on Emerging Infections. The content of those sections is based on the presentations and the discussions that took place during the workshop.
Support for this project was provided by the U.S. Department of Health and Human Services’ National Institutes of Health, Centers for Disease Control and Prevention, and Food and Drug Administration; U.S. Department of State, Bureau of Oceans and International Environmental and Scientific Affairs; U.S. Department of Veterans Affairs; Abbott Laboratories; American Society for Microbiology; Applied Microbiology, Inc.; Bristol-Myers Squibb Company; Burroughs Wellcome Fund; Eli Lilly & Company; Glaxo Wellcome; Hoffmann-La Roche; Merck; Pfizer; SmithKline Beecham; and Wyeth-Ayerst Laboratories.
The views presented are those of the editor and speakers and are not necessarily those of the funding organizations.
NOTICE: The project that is the subject of this workshop summary was approved by the Governing Board of the National Research Council, whose members are drawn from the councils of the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine.